Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients
Status:
RECRUITING
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
To evaluate: The radiographic progression-free survival (rPFS) of metastatic hormone-sensitive prostate cancer (mHSPC) patients treated with androgen deprivation therapy (ADT) + second-generation antiandrogens±chemotherapy combined with cytoreductive prostatectomy (CRP)
Phase:
PHASE3
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Treatments:
Brachytherapy Drug Therapy Surgical Procedures, Operative